MedTrace Logo

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

NCT00308048 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 435

Last updated 2011-07-06

No results posted yet for this study

Summary

Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

Conditions

  • Hepatitis C Virus Infection

Interventions

DRUG

Pegylated Interferon alfa 2b and ribavirin

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Ullevaal University Hospital

    lead OTHER

Principal Investigators

  • Olav Dalgard, MD PhD · Ullevaal University Hospital, Oslo, Norway

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2006-09-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308048 on ClinicalTrials.gov